Kenny J Watson
Overview
Explore the profile of Kenny J Watson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franzese R, McFadyen L, Watson K, Riccobene T, Carrothers T, Vourvahis M, et al.
Clin Pharmacol Ther
. 2021 Oct;
111(3):635-645.
PMID: 34687548
Increasing prevalence of infections caused by antimicrobial-resistant gram-negative bacteria represents a global health crisis, and while several novel therapies that target various aspects of antimicrobial resistance have been introduced in...
2.
Trifilieff A, Ethell B, Sykes D, Watson K, Collingwood S, Charlton S, et al.
Toxicol Appl Pharmacol
. 2015 Jun;
287(1):9-16.
PMID: 26026369
Long acting inhaled muscarinic receptor antagonists, such as tiotropium, are widely used as bronchodilator therapy for chronic obstructive pulmonary disease (COPD). Although this class of compounds is generally considered to...
3.
Jones H, Gardner I, Collard W, Stanley P, Oxley P, Hosea N, et al.
Clin Pharmacokinet
. 2011 Apr;
50(5):331-47.
PMID: 21456633
Background: The importance of predicting human pharmacokinetics during compound selection has been recognized in the pharmaceutical industry. To this end there are many different approaches that are applied. Methods: In...
4.
Watson K, Davis J, Jones H
Drug Metab Dispos
. 2011 Apr;
39(7):1203-13.
PMID: 21451120
5-[2-Ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-pyridin-3-yl]-3-ethyl-2-(2-methoxy-ethyl)-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (UK-369,003) is a phosphodiesterase-5 inhibitor in clinical development at Pfizer. UK-369,003 is predominantly metabolized by cytochrome P450 3A4 and is also a substrate for the efflux transporter P-glycoprotein. The...
5.
Watson K, Gorczyca W, Umland J, Zhang Y, Chen X, Sun S, et al.
J Pharmacol Toxicol Methods
. 2011 Mar;
63(3):304-13.
PMID: 21419854
Introduction: Delayed ventricular repolarisation is manifested electrocardiographically in a prolongation of the QT interval. Such prolongation can lead to potentially fatal Torsades de Pointes. Moxifloxacin is a fluoroquinolone antibiotic which...
6.
Jones H, Gardner I, Watson K
AAPS J
. 2009 Mar;
11(1):155-66.
PMID: 19280352
Physiologically based pharmacokinetic (PBPK) models are composed of a series of differential equations and have been implemented in a number of commercial software packages. These models require species-specific and compound-specific...